Xoft raises $25M for targeted cancer treatment
Xoft, a Sunnyvale, Calif. company with an X-ray radiation treatment used for breast cancer and endometrial cancer, has raised a fifth round totaling $25 million, according to VentureWire.
The treatment uses targeting technology and tools to pinpoint the area being irradiated, limiting the damage done to the patient and allowing technicians to remain in the room.
New investor Chicago Growth Partners provided a majority of the funding, and was joined by previous investors including Easton Capital, Cutlass… Continue Reading
Life sciences briefing: Wednesday, Aug. 29, 2007
(UPDATED at 3:10pm PT: See below.)
Featured companies: Agendia, EndoGastric Solutions, FlowCo, Gentris, MedManage Systems, ParagonDx, Presidio Pharmaceuticals, Xoova
Presidio Pharma raises $26M for viral treatments — San Francisco’s Presidio Pharmaceuticals, a biotech developing new antiviral drugs, raised $26 million in a second funding round. Investors included Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West Capital, Nexus Medical Partners, Sagamore Bioventures, George Rathmann Fund and Peninsula Overview Partners.
Presidio’s lead drug candidates take aim at HIV, hepatitis… Continue Reading
Vascular biology biotech TargeGen raises $40M
San Diego’s TargeGen, a biotechnology targeting disease treatments related to abnormal blood-vessel growth, raised $40 million in a fourth funding round. New investors included Innovis Investments, VantagePoint Venture Partners and CTI Life Sciences Fund, joined by existing investors Forward Ventures, Enterprise Partners, Chicago Growth Partners.
TargeGen’s potential disease targets range from eye diseases such as age-related macular degeneration (AMD) to cancer to heart disease. Its leading drug candidate, TG100801, completed an early-stage phase I trial in… Continue Reading